Peptide mimotopes recognized by antibodies cetuximab and matuzumab induce a functionally equivalent anti-EGFR immune response

摘要: Aberrant activation of the epidermal growth factor receptor (EGFR) has been found in human cancers various origins, and implicated cancer pathogenesis. The therapeutic anti-EGFR antibodies cetuximab matuzumab inhibit both ligand-induced EGFR-expressing tumor cells. efficacy such EGFR-targeted therapies may be further enhanced by induction functionally equivalent endogenous antibody responses. Here we describe novel peptide sequences selected from random libraries for binding to single-chain fragments or matuzumab. Two these peptides characterized KTL YPLG motifs are recognized equally well matuzumab, although nonoverlapping epitopes were previously reported antibodies. Immunization experimental animals with synthetic KTL- YPLG-containing led that cross-react EGFR, prevent natural EGFR ligands, cell a manner similar Our findings show mimotopes can induce antitumoral activity, which have implications EGFR-specific immunotherapy.